Alan Cowan: Buprenorphine from the bench to the bedside—Personal notes

Saadet Inan, MD, PhD; Michael Guarnieri, PhD, MPH

doi:10.5055/jom.2021.0637

Authors

Saadet Inan, MD, PhD
Michael Guarnieri, PhD, MPH https://orcid.org/0000-0002-3079-6746

DOI:

https://doi.org/10.5055/jom.2021.0637

Keywords:

buprenorphine, sustained-release

Abstract

In 2005, Bob Adams, the Chief Veterinarian at Johns Hopkins, wondered if sustained release technology could be used to improve postsurgical analgesia for animal medicine. Henry Brem, Director of the Hunterian Laboratories, had organized an international consortium to advance therapy for brain tumors and stroke. The Hunterian had over 20 years of experience with the safety and effectiveness of neutral lipids, phospholipids, carbohydrates, gels, polymers, and assorted devices for sustained-release drug delivery. We had the technology. What was the best pharmacology? Buprenorphine was the obvious analgesic. Reports of adverse events in the veterinary literature were rare.

Author Biographies

Saadet Inan, MD, PhD

Center for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania

Michael Guarnieri, PhD, MPH

Pediatric Neurosurgery, Johns Hopkins Neurosurgical Hunterian Laboratory, Baltimore, Maryland

References

Campbell ND, Lovell AM: Addiction reviews the history of the development of buprenorphine as an addiction therapeutic. Ann N Y Acad Sci. 2012; 1248: 124-139. DOI:10.1111/j.1749-6632.2011.0635.x.

Cowan A, Doxey JC, Harry EJ: The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol. 1977; 60(4): 547-554. DOI:10.1111/j.1476-5381.1977.tb07533.x.

Cowan A, Lewis JW, Macfarlane IR: Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol. 1977; 60(4): 537-545. DOI:10.1111/j.1476-5381.1977.tb07532.x.

Cowan A: Use of the mouse jumping test for estimating antagonistic potencies of morphine antagonists. J Pharm Pharmacol. 1976; 28(3): 177-182. DOI:10.1111/j.2042-7158.1976.tb04126.x.

Porreca F, Cowan A, Raffa RB, et al.: Estimation in vivo of the receptor constants of morphine in naive and morphine-tolerant rats. Life Sci. 1982; 31(20-21): 2355-2358. DOI:10.1016/0024-3205(82)90155-2.

Porreca F, Raffa RB, Cowan A, et al.: A comparison of the receptor constants of morphine and ethylketocyclazocine for analgesia and inhibition of gastrointestinal transit in the rat. Life Sci. 1982; 31(18): 1955-1961. DOI:10.1016/0024-3205(82)90034-0.

Tallarida RJ, Cowan A: The affinity of morphine for its pharmacologic receptor in vivo. J Pharmacol Exp Ther. 1982; 222(1): 198-201. PMID: 6283067.

Knoll AT, Carlezon Jr WA: Dynorphin, stress, and depression. Brain Res. 2010; 1314: 56-73.

Chavkin C, Koob GF: Dynorphin, dysphoria, and dependence: The stress of addiction. Neuropsychopharmacology. 2016; 41: 373-374.

Liu S, Pickens S, Burma NE, et al.: Kappa opioid receptors drive a tonic aversive component of chronic pain. J Neurosci. 2019; 39(21): 4162-4178.

Bershad AK, Jaffe JH, Childs E, et al.: Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans. Psychoneuroendocrinology. 2015; 52: 281-288. DOI:10.1016/j.psyneuen.2014.12.004.

Browne CA, Falcon E, Robinson SA, et al.: Reversal of stress-induced social interaction deficits by buprenorphine. Int J Neuropsychopharmacol. 2018; 21(2): 164-174.

Li W, Sun H, Chen H, et al.: Major depressive disorder and kappa opioid receptor antagonists. Transl Perioper Pain Med. 2016; 1(2): 4-16.

Bershad AK, Ruiz NA, de Wit H: Effects of buprenorphine on responses to emotional stimuli in individuals with a range of mood symptomatology. Int J Neuropsychopharmacol. 2018; 21(2): 120-127.

Gmerek DE, Cowan A: An animal model for preclinical screening of systemic antipruritic agents. J Pharmacol Methods. 1983; 10: 107-112.

Sun YG, Chen ZF: A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature. 2007; 448: 700-703.

Gmerek DE, Cowan A: In vivo evidence for benzomorphan-selective receptors in rat. J Pharmacol Exp Ther. 1984; 230: 110-115.

Cowan A, Kehner GB: Antagonism by opioids of compound 48/80-induced scratching in mice. Br J Pharmacol. 1997; 122 (suppl.): 169P.

Cowan A, Inan S, Kehner GB: GNTI, a kappa opioid receptor antagonist, causes compulsive scratching in mice. Pharmacologist. 2002; 44: A51.

Inan S, Cowan A: Kappa opioid agonists suppress chloroquine-induced scratching in mice. Eur J Pharmacol. 2004; 502: 233-237.

Inan S, Cowan A: Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats. Pharmacol Boichem Behav. 2006; 85: 39-43.

Inan S, Dun NJ, Cowan A: Nalfurafine prevents GNTI- and compound 48/80-induced spinal cfos expression and attenuates GNTI-elicited scratching behavior in mice. Neuroscience. 2009; 163: 23-33.

Inan S, Torres-Huerto A, Jensen LE, et al.: Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis. Eur J Pharmacol. 2019; 864: 172702.

Kardon AP, Polgar E, Hachisuka J, et al.: Dynorphin acts as a neuromodulator to inhibit itch in the dorsal horn of the spinal cord. Neuron. 2014; 82: 573-586.

Kumagai H, Ebata T, Takamori K, et al.: Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients. Am J Nephrol. 2012; 36: 175-183.

Fishbane S, Jamal A, Munera C, et al.: A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med. 2020; 382: 322-232.

Available at https://www.trevitherapeutics.com/pipeline/. Accessed December 15, 2020.